Kathleen Wyne, MD
Endocrinology, Diabetes & Metabolism · Columbus, OHNPI 1497731640
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $69,189 of the $88,433 with a category attached, or 78.2%. 16 manufacturers reported payments, led by Novo Nordisk at 24.9% of the total. Reporting peaked in 2019 at $27,902 and has fallen 53.3% since, to $13,025 in 2025. Among endocrinology, diabetes & metabolism clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 56 payments — averaging $1579.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$22K
- AstraZeneca$13K
- Sanofi-aventis U.S. LLC$12K
- AbbVie$10K
- Ipsen Bioscience Inc.$10K
- Esperion Therapeutics, Inc.$5K
- plus $17K from 10 others
Across 180 payments — averaging $2343.78 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Chiesi USA, Inc.$88K
- Amryt Pharma Holdings Ltd$71K
- Genentech, Inc.$68K
- AbbVie$60K
- Intercept Pharma Europe Ltd.$48K
- Sanofi US Services Inc.$43K
- plus $44K from 3 others
What the payments were for
- Consulting fees$69,18978%
- Speaking & faculty fees$11,29913%
- Travel & lodging$6,2097%
- Food & beverage$1,2021%
- Education$1500%
- Gifts$590%
- Other$3250%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 11 | $21,994 |
| AstraZeneca | 3 | $12,595 |
| Sanofi-aventis U.S. LLC | 6 | $12,180 |
| AbbVie | 2 | $9,800 |
| Ipsen Bioscience Inc. | 1 | $9,690 |
| Esperion Therapeutics, Inc. | 3 | $5,480 |
| Madrigal Pharmaceuticals | 7 | $4,482 |
| Amryt Pharma Holdings Ltd | 2 | $3,252 |
| Gilead | 4 | $3,116 |
| Merck | 8 | $1,770 |
| Bayer | 1 | $1,748 |
| Novartis | 2 | $1,557 |
| Abbott | 3 | $475 |
| Eli Lilly | 1 | $173 |
| Astrazeneca UK Limited | 1 | $61 |
| Mannkind Corporation | 1 | $59 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$88,433 in reported general payments places this provider in the 90th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
See all endocrinology, diabetes & metabolism providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 93 | $69,552 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 47 | $57,023 |
| TrulicityDulaglutide | 54 | $56,891 |
| ArexvyRsvpref3 Antigen/As01e/Pf | 188 | $55,556 |
| Tresiba Flextouch U-100Insulin Degludec | 78 | $54,000 |
| OzempicSemaglutide | 14 | $24,213 |
| JardianceEmpagliflozin | 30 | $21,507 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 96 | $20,082 |
| FiaspInsulin Aspart (Niacinamide) | 12 | $17,167 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $14,878 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 81 | $9,450 |
| BaqsimiGlucagon | 14 | $8,885 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 64 | $8,131 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 24 | $7,672 |
| Novolog FlexpenInsulin Aspart | 38 | $7,491 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Fiasp, Novolog | $21,994 | $46,30143 claims |
| AbbVieSynthroid | $9,800 | $1,76327 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 312 endocrinology, diabetes & metabolism providers in Ohio.
Other endocrinology, diabetes & metabolism in Columbus
- Elena ChristofidesColumbus$2.3M
- Samuel AndersonColumbus$556K
- Ravi DhawaleColumbus$175K
- Laura RyanColumbus$126K
- Kathleen DunganColumbus$60K
- Jay PatelColumbus$60K
- Lawrence KirschnerColumbus$57K
- Shrikant TamhaneColumbus$55K
- Constantine KroustosColumbus$53K
- Laura ButzColumbus$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.